Publication in The Lancet Oncology of a study led by Christos Chouaid (CHI Créteil – Service de Pneumologie, IMRB-U955 Bastuji-Garin team) on the benefits of a new treatment for patients with recurrent small cell lung cancer

Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small cell lung cancer.

This study led by Prof. Christos Chouaid (Department of Pneumology at the CHI de Créteil – IMRB U955, Bastuji-Garin team) aimed to determine whether the carboplatin plus etoposide doublet was superior to Topotecan as a second-line treatment in patients with sensitive and recurrent small cell lung cancer. This trial was conducted in 38 hospitals in France and 162 patients were recruited for this study between July 18, 2013 and July 2, 2018.

Our results suggest that carboplatin plus etoposide relapse can be considered a reasonable second-line chemotherapy option for patients with sensitive and recurrent small cell lung cancer.

Read more: Lancet Oncology: Volume 21, ISSUE 9, P1224-1233, September 01, 2020